ArriVent BioPharma
AVBP
54 hedge funds and large institutions have $404M invested in ArriVent BioPharma in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 7 reducing their positions, and 11 closing their positions.
229% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 7
2% more funds holding
Funds holding: 53 → 54 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3.71% less ownership
Funds ownership: 68.37% → 64.66% (-3.7%)
13% less capital inflows, than outflows
Capital inflows: $23.5M | Capital outflows: $27.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$9.9M |
| 2 |
Novo Holdings A/S
Hellerup,
Denmark
|
+$7.54M |
| 3 |
Suvretta Capital Management
New York
|
+$2.66M |
| 4 |
Hidden Lake Asset Management
New York
|
+$662K |
| 5 |
State Street
Boston,
Massachusetts
|
+$559K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.12M |
| 2 |
Millennium Management
New York
|
-$3.56M |
| 3 |
Farallon Capital Management
San Francisco,
California
|
-$2.71M |
| 4 |
Octagon Capital Advisors
New York
|
-$2.51M |
| 5 |
MYDA Advisors
Woodmere,
New York
|
-$536K |
AVBP Hedge Fund Activity: Q2 2024 in Review
54 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q2 2024, worth a combined $404M — up 3.9% from $389M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AVBP positions and 11 closed out — a net gain of 1 holder — while 23 added to existing stakes and 7 trimmed.
The largest buyer was HHLR Advisors, adding an estimated $9.9M. The largest seller was Citadel Advisors, exiting entirely with an estimated $5.12M sold.
- 54 institutional investors held ArriVent BioPharma (AVBP) as of Q2 2024, up from 53 in Q1 2024.
- Funds reported $404M of ArriVent BioPharma stock for Q2 2024, up 3.9% quarter-over-quarter.
- 12 funds opened new ArriVent BioPharma positions in Q2 2024 and 11 closed out, a net change of +1 holder.
- The largest ArriVent BioPharma buyer in Q2 2024 was HHLR Advisors, an estimated $9.9M added.
- The largest ArriVent BioPharma seller in Q2 2024 was Citadel Advisors, an estimated $5.12M sold.
Based on aggregated 13F filings for Q2 2024.